Actively Recruiting
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Led by Regeneron Pharmaceuticals · Updated on 2026-04-09
860
Participants Needed
12
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
CONDITIONS
Official Title
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with histologically confirmed malignant solid tumors that are locally advanced or metastatic
- Khorana thromboembolic risk score of 2 or higher, or a known tumor genetic variant linked to higher risk of blood clots
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 at screening and before first dose
You will not qualify if you...
- Known bleeding disorders such as Hemophilia A or B, von Willebrand's disease, or hemorrhagic tumor sites
- Cancer diagnosis only consisting of basal cell or squamous cell skin carcinoma
- Primary brain tumor or brain metastases
- History of blood clots or arterial thromboembolism requiring anticoagulation
- Any condition that may interfere with study results or increase risk as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Bioresearch Partner- Hialeah Hospital
Hialeah, Florida, United States, 33013
Actively Recruiting
2
Helios Clinical Research
North Miami Beach, Florida, United States, 33169
Actively Recruiting
3
El Paso Medical Research Institute (Medresearch Inc)
El Paso, Texas, United States, 79902
Actively Recruiting
4
LTD High Technology Hospital Medcenter
Batumi, Adjara, Georgia, 6000
Actively Recruiting
5
Krystyna Kiel Oncology Center
Kutaisi, Imereti, Georgia, 4600
Actively Recruiting
6
American Hospital Tbilisi
Tbilisi, Georgia, 0102
Actively Recruiting
7
Llc Todua Clinic
Tbilisi, Georgia, 0112
Actively Recruiting
8
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
Tbilisi, Georgia, 0144
Actively Recruiting
9
Institute of Clinical Oncology
Tbilisi, Georgia, 0159
Actively Recruiting
10
JSC Evex Hospitals - Caraps Medline
Tbilisi, Georgia, 0179
Actively Recruiting
11
LTD Cancer Research Centre
Tbilisi, Georgia, 0179
Actively Recruiting
12
Caucasus Medical Centre
Tbilisi, Georgia, 0186
Actively Recruiting
Research Team
C
Clinical Trials Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here